Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12060762 | 0.85 | ALDH1A1 (0.45) | DHFRSIGMAR1MCL1CYP1A2CYP2D6 | |
| SCHEMBL17934765 | 0.82 | SIGMAR1 (0.39) | SIGMAR1CYP1A1CYP1B1CYP1A2CYP2D6 | |
| SCHEMBL1414206 | 0.78 | SIGMAR1 (0.57) | DHFRSIGMAR1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5613021 | 0.78 | CYP1A1 (0.41) | SIGMAR1CYP1A1CYP1B1CYP1A2CYP2C19 | |
| SCHEMBL12048739 | 0.78 | SIGMAR1 (0.50) | DHFRSIGMAR1MCL1CYP1A2CYP2C19 | |
| SCHEMBL12048709 | 0.76 | SIGMAR1 (0.49) | DHFRSIGMAR1MCL1CYP1A1CYP1B1 | |
| SCHEMBL14465459 | 0.76 | SIGMAR1 (0.49) | DHFRSIGMAR1MCL1ABCG2 | |
| SCHEMBL12258277 | 0.76 | DHFR (0.49) | DHFRSIGMAR1MCL1CYP1A2CYP2D6 | |
| SCHEMBL1683320 | 0.74 | SIGMAR1 (0.63) | DHFRSIGMAR1MCL1CYP1A2CYP2D6 | |
| SCHEMBL12048742 | 0.74 | DHFR (0.45) | DHFRSIGMAR1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220371-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | claimed |
| US-20070077641-A1 | Methionine aminopeptidase and methods of use | PALMER LESLIE | 2007-04-05 | — | — | US | disclosed |
| EP-1624849-A2 | METHIONINE AMINOPEPTIDASE AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005016237-A2 | METHIONINE AMINOPEPTIDASE AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050004116-A1 | 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | disclosed |
| US-20030220371-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | disclosed |
| EP-1274424-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1274424-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001078723-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004116-A1 | 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents | METAP1, METAP2, DNPEP | DHFR 234/4885SIGMAR1 2679/4885MCL1 902/4885 |
| US-20030220371-A1 | Compounds and methods | METAP2, METAP1, DNPEP | DHFR 181/4885SIGMAR1 4130/4885MCL1 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.